We know that paralysis can be very destructive because due to the blood clot stuck in the cerebral vein, important parts of the brain start to be destroyed in an irreversible way due to lack of oxygen and blood. In this way, a brand-new protein therapy has been made that can greatly slow down the loss of paralysis.
According to scientists at the University of Oslo, stroke damage can be reduced by inserting specific proteins after paralysis. A few hours after the mice became paralyzed, the first test showed very promising results that could stop this problem from getting worse. However, the destination of human trials is still a long way off.
“The negative brain changes caused by paralysis become a disease of the whole age, every minute of paralysis becomes destructive for the brain and the need for mental protective measures after the attack has always been felt. In this therapy, we have focused on a blood protein, ‘Factor Seven Activating Protease’ (FSAP),” said Dr Sandeep Kanse, head of the study.
After paralysis, the amount of FASP in the blood increases and it has also been seen in stroke patients. Scientists wanted to know how fasp production in mice could be affected in case of paralysis if they were completely stopped genetically or otherwise. But in this case, the experts’ assessment turned out to be wrong and the brain of the rats was more damaged.
In the next stage, fsap was inserted by making the mice a patient of paralysis, its good effects were seen. That’s why protein therapy has been devised.
Currently, tissue plasminogen activator or TPA, a treatment after severe stroke, is prevalent around the world, which immediately dissolves the clots trapped in the nerves of the brain and widens the veins. But it is important that the sooner it is vaccinated, it benefits, but still only one-third of the people benefit from it.
Mice that were given FSAP with tPA showed a significant improvement compared to mice with tPA therapy alone. New protein therapy combined with tPA is expected to prevent further brain damage after stroke. However, more research and trials are needed before humans.